Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157144 | 0.82 | TSHR (0.37) | TSHRALOX15GABRA1GABRB2ALDH1A1 | |
| SCHEMBL10615720 | 0.79 | PTPN9 (0.35) | TSHRALOX15GABRA1GABRB2ALDH1A1 | |
| SCHEMBL19362158 | 0.75 | POLB (0.34) | TSHRALOX15GABRA1GABRB2POLB | |
| SCHEMBL6580109 | 0.74 | PTPN9 (0.34) | TSHRALOX15GABRA1GABRB2ALDH1A1 | |
| SCHEMBL27901422 | 0.71 | ALDH1A1 (0.57) | TSHRKMT2AGABRA1GABRB2LMNA | |
| Hydrochloric Acid SCHEMBL27524511 | 0.70 | GABRA1 (0.44) | TSHRKMT2AMEN1GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL8622407 | 0.70 | GABRA1 (0.44) | TSHRKMT2AMEN1GABRA1GABRB2 | |
| SCHEMBL18177743 | 0.70 | GABRA1 (0.47) | TSHRKMT2AGABRA1GABRB2LMNA | |
| SCHEMBL31517035 | 0.70 | GABRA1 (0.52) | TSHRKMT2AMEN1GABRA1GABRB2 | |
| SCHEMBL1345444 | 0.70 | GABRA1 (0.52) | TSHRKMT2AMEN1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191368-A1 | Inhibition of tissue damage to skin from radiation treatment therapy | BISSETT DONALD L | 2007-08-16 | — | — | US | claimed |
| WO-2003002119-A1 | TREATMENT AND PREVENTION OF LIPODERMATOSCLEROSIS | JOHNSON & JOHNSON MEDICAL LIMITED (GB) | 2003-01-09 | — | — | WO | claimed |
| US-5487884-A | CYTOPROTECTIVE AGENTS BY RADIATION RESISTANCE TO PREVENT SKIN CANCER AND PREMATURE AGING | THE PROCTER & GAMBLE COMPANY (US) | 1996-01-30 | — | — | US | claimed |
| EP-0496434-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1992-07-29 | — | — | EP | claimed |
| EP-0313305-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-26 | — | — | EP | claimed |
| WO-2008035152-A1 | COSMETIC METHOD TO REMOVE THE DARK UNDEREYE MARKS | GHISALBERTI CARLO (BR) | 2008-03-27 | — | — | WO | disclosed |
| US-20070191368-A1 | Inhibition of tissue damage to skin from radiation treatment therapy | BISSETT DONALD L | 2007-08-16 | — | — | US | disclosed |
| US-20050020672-A1 | Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals | THE PROCTER & GAMBLE COMPANY | 2005-01-27 | — | — | US | disclosed |
| WO-2003002119-A1 | TREATMENT AND PREVENTION OF LIPODERMATOSCLEROSIS | JOHNSON & JOHNSON MEDICAL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
| US-5922758-A | REDUCING OR PREVENTING OZONE, SMOKE AND/OR POLLUTION DAMAGE TO MAMMALIAN SKIN BY APPLYING A MAMMALIAN SKIN AN EFFECTIVE AMOUNT OF COMPOUND SELECTED FROM 2,4-DIENOIC ACID ESTER OF TOCOPHEROLS, SUCH AS ALPHA, BETA, ZETA1, ZETA2 AND OTHERS | THE PROCTER & GAMBLE COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| US-5739156-A | ADMINISTERING TO REDUCE NONULTRAVIOLET-INDUCED FREE RADICAL DAMAGE OR AGING | THE PROCTER & GAMBLE COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5487884-A | CYTOPROTECTIVE AGENTS BY RADIATION RESISTANCE TO PREVENT SKIN CANCER AND PREMATURE AGING | THE PROCTER & GAMBLE COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0496433-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0496434-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0313305-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020672-A1 | Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals | TXNRD2, PRDX5, PLPBP | TSHR 918/4885KMT2A 1101/4885MEN1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.